Recent Posts
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
- Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA
- Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.
- Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.
- Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs
Archives
- No comments have been published yet.
Find us on Facebook
Archives
Recent Posts
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
- Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA
- Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.
- Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.
- Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs
Recent Tweets
-
Keep your Avada theme maintained & updated. Update your plugins, schedule regular backups, apply all patches. If yo… twitter.com/i/web/status/1…
3 days ago -
@CharlyyCS_14 @ayudawp Thank you. You did create a ticket to which our team replied well within our stipulated repl… twitter.com/i/web/status/1…
3 days ago -
@EDTACorg You support ticket has been replied to by our team earlier, please check your email inbox. Our support po… twitter.com/i/web/status/1…
3 days ago
Recent Comments